

NFKappaB-p105 Polyclonal Antibody

Description

Product type	Primary Antibody
Code	BT-AP05977
Host	Rabbit
Isotype	IgG
Size	20ul, 50ul, 100ul
Immunogen	The antiserum was produced against synthesized peptide derived from human NF-kappaB p105/p50. AA range:899-948
Mol wt	105356
Species reactivity	Human, Mouse, Rat
Clonality	Polyclonal
Recommended application	WB, IHC-p, ELISA
Concentration	1 mg/ml
Full name	NFkappaB-p105 Antibody
Synonyms	NFKB1; Nuclear factor NF-kappa-B p105 subunit; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

This product is for research use only, not for use in human, therapeutic or diagnostic procedure.


Background


NFKB1 encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed.

Recommended Dilution

WB: 1: 500 - 1: 2000 IHC: 1: 100 - 1: 300 ELISA: 1: 20000 Not yet tested in other applications.

Images





Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using NFkappaB p105/p50 Antibody. The picture on the right is blocked with the synthesized peptide.

Western blot analysis of lysates from HeLa cells, treated with CA+TNF 20ng/ml 10', using NFkappaB p105/p50 Antibody. The lane on the right is blocked with the synthesized peptide. 501 Changsheng S Rd, Nanhu Dist, Jiaxing, Zhejiang, China

Tel: 86 21 31007137 | E-mail: save@bt-laboratory.com | www.bt-laboratory.com